PT2491028E - Compostos de indazole e pirazolopiridina como antagonistas do receptor ccr1 - Google Patents
Compostos de indazole e pirazolopiridina como antagonistas do receptor ccr1 Download PDFInfo
- Publication number
- PT2491028E PT2491028E PT107683567T PT10768356T PT2491028E PT 2491028 E PT2491028 E PT 2491028E PT 107683567 T PT107683567 T PT 107683567T PT 10768356 T PT10768356 T PT 10768356T PT 2491028 E PT2491028 E PT 2491028E
- Authority
- PT
- Portugal
- Prior art keywords
- indazole
- receptor antagonists
- ccr1 receptor
- pyrazolopyridine compounds
- pyrazolopyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25359009P | 2009-10-21 | 2009-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2491028E true PT2491028E (pt) | 2014-02-04 |
Family
ID=43126891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107683567T PT2491028E (pt) | 2009-10-21 | 2010-10-19 | Compostos de indazole e pirazolopiridina como antagonistas do receptor ccr1 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9056858B2 (pt) |
| EP (1) | EP2491028B1 (pt) |
| JP (1) | JP5542946B2 (pt) |
| KR (1) | KR20120087923A (pt) |
| CN (1) | CN102666526A (pt) |
| AP (1) | AP2012006204A0 (pt) |
| AU (1) | AU2010308277A1 (pt) |
| BR (1) | BR112012009331A2 (pt) |
| CA (1) | CA2778060A1 (pt) |
| CL (1) | CL2012000967A1 (pt) |
| CO (1) | CO6531488A2 (pt) |
| DK (1) | DK2491028T3 (pt) |
| EA (1) | EA021015B1 (pt) |
| EC (1) | ECSP12011904A (pt) |
| ES (1) | ES2444780T3 (pt) |
| GE (1) | GEP20146103B (pt) |
| HR (1) | HRP20140213T1 (pt) |
| IL (1) | IL218823A0 (pt) |
| IN (1) | IN2012DN03449A (pt) |
| MA (1) | MA33675B1 (pt) |
| MX (1) | MX2012004644A (pt) |
| NZ (1) | NZ599132A (pt) |
| PE (1) | PE20121433A1 (pt) |
| PL (1) | PL2491028T3 (pt) |
| PT (1) | PT2491028E (pt) |
| RS (1) | RS53130B (pt) |
| SI (1) | SI2491028T1 (pt) |
| TN (1) | TN2012000180A1 (pt) |
| WO (1) | WO2011049917A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008327B2 (en) | 2008-04-29 | 2011-08-30 | Boehringer Ingelheim International Gmbh | Indazole compounds as CCR1 receptor antagonists |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| CN102227425A (zh) | 2008-09-26 | 2011-10-26 | 贝林格尔·英格海姆国际有限公司 | 作为ccr1受体拮抗剂的氮杂吲唑化合物 |
| RS53130B (en) | 2009-10-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| WO2015160654A1 (en) | 2014-04-14 | 2015-10-22 | Boehringer Ingelheim International Gmbh | Compounds as modulators of ror gamma |
| CN112707831A (zh) * | 2021-02-05 | 2021-04-27 | 阿里生物新材料（常州）有限公司 | 一种3-（1-氨基环丙基）苯甲酸甲酯的合成方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338625C (en) | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| ATE231505T1 (de) | 1991-03-28 | 2003-02-15 | Eisai Co Ltd | Neue heterocyclische/cyclische amine |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| WO1994001415A1 (en) | 1992-07-03 | 1994-01-20 | Kumiai Chemical Industry Co., Ltd. | Condensed heterocyclic derivative and weedkiller |
| CN1048246C (zh) | 1993-06-25 | 2000-01-12 | 组合化学工业株式会社 | 吲唑磺酰脲类衍生物、用途及其制造中的中间体 |
| US6025374A (en) | 1994-12-06 | 2000-02-15 | Merck Sharp & Dohme, Ltd. | Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| CA2240439A1 (en) | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
| GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| ID24942A (id) | 1997-11-04 | 2000-08-31 | Pfizer Prod Inc | Senyawa terapi aktif yang berdasarkan penggantian bioisoster katekol dengan indazole pada inhibitor pde4 |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| EP1192135A2 (en) | 1999-06-14 | 2002-04-03 | Eli Lilly And Company | Serine protease inhibitors |
| AU5895500A (en) | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| CA2399642C (en) | 2000-03-02 | 2006-08-22 | Ndc Infrared Engineering Limited | Electromagnetic detection apparatus |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| ES2338539T3 (es) | 2001-11-01 | 2010-05-10 | Icagen, Inc. | Pirazolamidas para uso en el tratamiento del dolor. |
| EP1497278B1 (en) | 2002-04-11 | 2010-05-26 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic amide derivatives as cytokine inhibitors |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| CN1867336B (zh) | 2002-06-12 | 2010-05-12 | 凯莫森特里克斯股份有限公司 | 1-芳基-4-取代的哌嗪衍生物及其制药用途 |
| US7138420B2 (en) | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| WO2005016929A1 (en) | 2003-08-15 | 2005-02-24 | Astrazeneca Ab | Fused heterocylcles as inhibitors of glutamate racemase (muri) |
| EP1855670A4 (en) | 2005-02-24 | 2010-05-05 | Merck Sharp & Dohme | BENZAZOLE POTENTIALIZERS OF METABOTROPIC GLUTAMATE RECEPTORS |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2007002667A2 (en) * | 2005-06-22 | 2007-01-04 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| SI1924561T1 (sl) | 2005-09-01 | 2013-02-28 | Eli Lilly And Company | 6-arilalkilamino-2,3,4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja |
| EP1940394A4 (en) | 2005-10-25 | 2009-07-08 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| EP2044055A4 (en) | 2006-07-21 | 2011-03-23 | Takeda Pharmaceutical | amide compounds |
| WO2008089459A1 (en) | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of mek |
| CN101687864A (zh) | 2007-06-26 | 2010-03-31 | 阿斯利康(瑞典)有限公司 | 作为组织蛋白酶k抑制剂的1-氰基环丙基-衍生物 |
| EP2188295A4 (en) | 2007-08-10 | 2011-11-16 | Crystalgenomics Inc | PYRIDINE DERIVATIVES AND METHODS OF USE |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| JP5485164B2 (ja) | 2007-11-29 | 2014-05-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−カルボン酸アミドの誘導体 |
| US8008327B2 (en) | 2008-04-29 | 2011-08-30 | Boehringer Ingelheim International Gmbh | Indazole compounds as CCR1 receptor antagonists |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| CN102227425A (zh) | 2008-09-26 | 2011-10-26 | 贝林格尔·英格海姆国际有限公司 | 作为ccr1受体拮抗剂的氮杂吲唑化合物 |
| RS53130B (en) | 2009-10-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| EA201200820A1 (ru) | 2009-12-08 | 2013-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов |
| US8871786B2 (en) | 2010-04-30 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as CCR1 receptor antagonists |
| WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2010
- 2010-10-19 RS RS20140024A patent/RS53130B/en unknown
- 2010-10-19 IN IN3449DEN2012 patent/IN2012DN03449A/en unknown
- 2010-10-19 US US13/499,939 patent/US9056858B2/en active Active
- 2010-10-19 AP AP2012006204A patent/AP2012006204A0/xx unknown
- 2010-10-19 DK DK10768356.7T patent/DK2491028T3/da active
- 2010-10-19 JP JP2012535292A patent/JP5542946B2/ja active Active
- 2010-10-19 EP EP10768356.7A patent/EP2491028B1/en active Active
- 2010-10-19 WO PCT/US2010/053142 patent/WO2011049917A1/en active Application Filing
- 2010-10-19 BR BR112012009331A patent/BR112012009331A2/pt not_active IP Right Cessation
- 2010-10-19 ES ES10768356.7T patent/ES2444780T3/es active Active
- 2010-10-19 EA EA201200602A patent/EA021015B1/ru not_active IP Right Cessation
- 2010-10-19 GE GEAP201012715A patent/GEP20146103B/en unknown
- 2010-10-19 KR KR1020127010143A patent/KR20120087923A/ko not_active Application Discontinuation
- 2010-10-19 CN CN2010800578454A patent/CN102666526A/zh active Pending
- 2010-10-19 AU AU2010308277A patent/AU2010308277A1/en not_active Abandoned
- 2010-10-19 MX MX2012004644A patent/MX2012004644A/es active IP Right Grant
- 2010-10-19 PT PT107683567T patent/PT2491028E/pt unknown
- 2010-10-19 NZ NZ599132A patent/NZ599132A/en not_active IP Right Cessation
- 2010-10-19 PE PE2012000493A patent/PE20121433A1/es not_active Application Discontinuation
- 2010-10-19 PL PL10768356T patent/PL2491028T3/pl unknown
- 2010-10-19 CA CA2778060A patent/CA2778060A1/en not_active Abandoned
- 2010-10-19 SI SI201030538T patent/SI2491028T1/sl unknown
-
2012
- 2012-03-25 IL IL218823A patent/IL218823A0/en unknown
- 2012-04-16 MA MA34779A patent/MA33675B1/fr unknown
- 2012-04-16 CL CL2012000967A patent/CL2012000967A1/es unknown
- 2012-04-19 TN TNP2012000180A patent/TN2012000180A1/en unknown
- 2012-04-26 CO CO12068976A patent/CO6531488A2/es active IP Right Grant
- 2012-05-16 EC ECSP12011904 patent/ECSP12011904A/es unknown
-
2014
- 2014-03-10 HR HRP20140213AT patent/HRP20140213T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2012006204A0 (en) | 2012-04-30 |
| ECSP12011904A (es) | 2012-10-30 |
| HRP20140213T1 (hr) | 2014-04-11 |
| EA021015B1 (ru) | 2015-03-31 |
| US9056858B2 (en) | 2015-06-16 |
| DK2491028T3 (da) | 2014-01-13 |
| WO2011049917A1 (en) | 2011-04-28 |
| NZ599132A (en) | 2014-05-30 |
| BR112012009331A2 (pt) | 2019-09-24 |
| CO6531488A2 (es) | 2012-09-28 |
| PL2491028T3 (pl) | 2014-05-30 |
| SI2491028T1 (sl) | 2014-03-31 |
| JP2013508376A (ja) | 2013-03-07 |
| CL2012000967A1 (es) | 2012-09-14 |
| CN102666526A (zh) | 2012-09-12 |
| CA2778060A1 (en) | 2011-04-28 |
| ES2444780T3 (es) | 2014-02-26 |
| KR20120087923A (ko) | 2012-08-07 |
| RS53130B (en) | 2014-06-30 |
| TN2012000180A1 (en) | 2013-12-12 |
| MX2012004644A (es) | 2012-05-08 |
| MA33675B1 (fr) | 2012-10-01 |
| EP2491028A1 (en) | 2012-08-29 |
| IL218823A0 (en) | 2012-06-28 |
| EP2491028B1 (en) | 2013-12-11 |
| EA201200602A1 (ru) | 2012-12-28 |
| US20120270870A1 (en) | 2012-10-25 |
| AU2010308277A1 (en) | 2012-04-26 |
| GEP20146103B (en) | 2014-05-27 |
| PE20121433A1 (es) | 2012-11-10 |
| IN2012DN03449A (pt) | 2015-10-23 |
| JP5542946B2 (ja) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL210857A0 (en) | Azaindazole compounds as ccr1 receptor antagonists | |
| IL218823A0 (en) | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists | |
| HK1188211A1 (zh) | 受體拮抗劑 | |
| AP3170A (en) | New CCR2 receptor antagonists and uses thereof | |
| ZA201202029B (en) | Androgen receptor antagonists and uses thereof | |
| EP2344497A4 (en) | AZAINDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | |
| IL212551A0 (en) | Cxcr4 receptor compounds | |
| HK1159621A1 (en) | Pyrazole derivatives used as ccr4 receptor antagonists | |
| EP2427430A4 (en) | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | |
| EP2480077A4 (en) | Novel pyrrolidines as glucagonone receptor agonists, compositions thereof, and methods of use | |
| HK1163063A1 (en) | Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity 5-ht2b -3- | |
| HK1179619A1 (en) | (3 -methylpyrrolidin- 3 - yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists (3---3-)- nk-3 | |
| EP2566494A4 (en) | CXCR4 RECEPTOR COMPOUNDS | |
| IL217965A0 (en) | Bicyclic heterocycles and their use as ccr2 receptor antagonists | |
| EP2539706A4 (en) | ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS | |
| IL223060A (en) | Non-competitive antagonists for the nicotinic receptor | |
| HK1186176A1 (en) | Glycine derivatives and their use as muscarinic receptor antagonists | |
| GB0901836D0 (en) | EP4 receptor antagonists | |
| GB0900754D0 (en) | EP4 Receptor antagonists | |
| GB0900755D0 (en) | Ep4 receptor antagonists | |
| GB0900756D0 (en) | EP4 Receptor antagonists | |
| ZA200906849B (en) | Mineralcorticoid receptor antagonists for the treatment of endomertriosis | |
| GB0922455D0 (en) | Ep2 receptor antagonists |